TL;DR
This study reveals that atorvastatin (ATV) protects against myocardial injury and inflammation following coronary microembolization (CME) by inhibiting a newly identified pathway involving the transcription factor Hif1a and the enzyme Ptgs2. This work highlights ferroptosis as a key player in CME-induced damage and suggests ATV as a promising therapeutic agent.
What Problem Does This Paper Address?
Coronary microembolization (CME) is a common and serious complication during percutaneous coronary intervention (PCI), leading to myocardial injury and inflammation, often without effective preventative treatments. While ferroptosis, a form of programmed cell death driven by iron-dependent lipid peroxidation, has been implicated in various cardiovascular diseases, its specific role in CME-induced damage and the underlying molecular mechanisms remained unclear. This paper aims to bridge this knowledge gap by investigating the involvement of ferroptosis in CME and exploring how atorvastatin (ATV), a widely used statin, might exert its protective effects.
Methods
The researchers established a rat model of CME by injecting microspheres into the left ventricle. They then employed several key techniques:
- Pharmacological Intervention: Rats were pretreated with deferoxamine (DFO), a known ferroptosis inhibitor, or atorvastatin (ATV) to assess their protective effects.
- Cardiac Function Assessment: Echocardiography was used to measure left ventricular ejection fraction (LVEF) and fractional shortening (FS), while serum cardiac troponin T (cTnT) levels were quantified as a marker of myocardial damage.
- Ferroptosis Markers: Levels of malondialdehyde (MDA), glutathione (GSH), and ferrous iron (Fe²⁺) were measured to assess lipid peroxidation and oxidative stress associated with ferroptosis. The expression of key ferroptosis-related genes/proteins like glutathione peroxidase 4 (Gpx4) and solute carrier family 7 member 11 (Slc7a11) was also analyzed.
- Inflammation Markers: Tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β) levels were measured at both mRNA and protein levels to quantify inflammation.
- Molecular Mechanism Investigation:
- Western Blotting and RT-qPCR: Used to assess the expression of various proteins and genes, including Hif1a, Ptgs2, Gpx4, Slc7a11, TNF-α, and IL-1β.
- Chromatin Immunoprecipitation (ChIP)-qPCR: Performed to determine if the transcription factor Hif1a directly binds to the promoter region of the Ptgs2 gene.
- RNA Interference (RNAi): Used to silence the expression of Ptgs2 and Hif1a to understand their specific roles.
- Transmission Electron Microscopy: Employed to visualize ultrastructural changes in mitochondria, a hallmark of ferroptosis.
Datasets
Not discussed in the paper. The study utilized a rat model and experimental measurements rather than pre-existing datasets.
Key Insights and Ideas
- Ferroptosis is a key driver of CME-induced myocardial injury: The study provides strong evidence that ferroptosis, characterized by increased MDA and Fe²⁺, and decreased GSH and Gpx4, is significantly activated following CME. This suggests that targeting ferroptosis could be a viable therapeutic strategy.
- Ptgs2 is a critical mediator of ferroptosis and inflammation in CME: The enzyme Ptgs2 was found to be upregulated in CME and its inhibition (via shRNA) significantly ameliorated both ferroptosis and inflammation, highlighting its central role.
- Hif1a directly regulates Ptgs2 expression: The research demonstrates that the transcription factor Hif1a binds to the promoter region of Ptgs2, suggesting a direct transcriptional control mechanism that is activated during CME. This uncovers a novel regulatory axis.
- Atorvastatin acts through the Hif1a/Ptgs2 pathway: The study reveals that ATV's protective effects against CME are mediated by its ability to inhibit the Hif1a/Ptgs2 axis, thereby reducing ferroptosis and inflammation. This provides a mechanistic explanation for ATV's cardioprotective effects in this context.
Key Results
- CME induces significant myocardial injury and inflammation: CME led to a 7-fold increase in cTnT, a ~40% reduction in LVEF, increased MDA (~2.5 fold) and Fe²⁺ (~1.5 fold), decreased GSH (~42%), and elevated TNF-α and IL-1β.
- Ferroptosis inhibition (DFO) reverses CME effects: DFO treatment reversed the increases in MDA and Ptgs2, restored GSH and Gpx4 levels, reduced TNF-α and IL-1β, improved LVEF by approximately 2-fold, and reduced cTnT by about 50%.
- Ptgs2 silencing ameliorates CME-induced damage: Silencing Ptgs2 also reversed ferroptosis markers, reduced inflammation, improved cardiac function (LVEF improved by approximately 2-fold), and decreased cTnT.
- Hif1a is upregulated in CME and binds to the Ptgs2 promoter: Hif1a expression was significantly increased post-CME, and ChIP-qPCR confirmed its binding to the Ptgs2 promoter, indicating Hif1a positively regulates Ptgs2.
- ATV inhibits Hif1a/Ptgs2 axis and protects the heart: ATV pretreatment suppressed the CME-induced upregulation of Hif1a and Ptgs2, improved cardiac function (LVEF ~34% elevation, cTnT ~1.8 fold decrease), and reduced ferroptosis and inflammatory markers.
Limitations and Future Work
- Animal Model: The study was conducted in a rat model. While valuable, further validation in other animal models or human studies would be beneficial to confirm these findings' translational relevance.
- Interaction of Cell Death Pathways: The authors mention that apoptosis and pyroptosis were previously shown to be involved in CME. Further research is needed to elucidate the complex interactions between ferroptosis and these other regulated cell death pathways in CME.
- Broader Implications of Ptgs2: While Ptgs2 is implicated here, its role in ferroptosis is still debated in some contexts. Further investigation into the precise mechanisms by which Ptgs2 contributes to ferroptosis in the heart would be valuable.
- Long-term Effects of ATV: The study focused on short-term effects. Investigating the long-term benefits and potential side effects of ATV in CME models would be important.
- Clinical Translation: The findings suggest ATV as a potential therapeutic agent for CME. Future work should focus on clinical trials to assess its efficacy and safety in patients undergoing PCI.
Summary updated